Attend the virtual annual meeting on June 3, 2026 to vote on the board's recommendations. The proposals are standard governance matters with no immediate financial impact.
KROS drugs
KROS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 23 $11.56entry
- T+1 · 7mo ago −0.43%α −1.22% · $11.51
- T+5 · 7mo ago −3.98%α −5.46% · $11.10
- T+20 · 6mo ago −5.02%α −9.65% · $10.98
- T+60 · 4mo ago −8.22%α −13.24% · $10.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics is holding its 2026 annual shareholder meeting virtually on June 3, 2026. The board recommends voting for the election of Jean-Jacques Bienaimé and Charles Newton as Class III directors, ratifying Deloitte & Touche LLP as auditors, and approving executive compensation.
Key Financial Metrics
Key Facts
- Annual meeting date: June 3, 2026
- Meeting will be held virtually
- Board recommends voting FOR all proposals
- Proposal 1: Elect Jean-Jacques Bienaimé and Charles Newton as Class III directors
- Proposal 2: Ratify Deloitte & Touche LLP as independent registered public accounting firm
- Proposal 3: Approve executive officer compensation
Financial Impact
Routine governance matters
Risk Factors
- Failure to ratify auditors could lead to regulatory issues
- Shareholder opposition to executive compensation could signal governance concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-046801 |
| Document: 0001104659-26-046801-index-headers.html | 0001104659-26-046801 |
| Document: 0001104659-26-046801-index.html | 0001104659-26-046801 |
| Document: 0001104659-26-046801.txt | 0001104659-26-046801 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers